3 results about "Nitroimidazole derivatives" patented technology

This invention discloses the use of a combination of nitroimidazole derivatives in the preparation of drugs for the prevention and treatment of drug-resistant tuberculosis, belonging to the field of biomedical technology. This invention fills the clinical research gap regarding the use of combination drugs of nitroimidazole derivatives in the prevention and treatment of drug-resistant tuberculosis, providing a method for its application in the preparation of drugs for this purpose. This invention demonstrates good therapeutic effects against drug-resistant tuberculosis by combining nitroimidazole derivatives with various other anti-tuberculosis drugs, and shows promise as a new drug for the prevention and treatment of drug-resistant tuberculosis.

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a D-proline modified 2-nitroimidazole derivative and application thereof. The radioactive preparation obtained by labeling the D-proline modified 2-nitroimidazole derivative with radionuclide is high in radiochemical purity and good in stability and has hypoxia selectivity. The compound has high uptake and good retention at tumor parts of tumor-bearing mice, the tumor / non-target ratio is high, the uptake of non-target organs such as liver and intestines is low, and the compound can be popularized and applied as a novel tumor hypoxia developer.

The present invention relates to the field of biopharmaceutical technology, and in particular, to use of a nitroimidazole derivative or a pharmaceutical combination in the preparation of a medicament against drug-sensitive tuberculosis. Animal studies, phase I and phase II clinical trials, and the optimization of dosage and route of administration have demonstrated that the nitroimidazole derivative has no significant drug accumulation, no significant reproductive toxicity, no significant cardiotoxicity, and no QT prolongation effects. Compared with existing drugs such as delamanid, the nitroimidazole derivative has shorter treatment time, more significant therapeutic effects, and higher safety. Especially in pulmonary images, the cavities in patients are significantly reduced, or the lesions are significantly absorbed, suggesting that the nitroimidazole derivative is promising as a novel drug for preventing and treating drug-sensitive tuberculosis.